Ivabradine Tablet
Product Images NDC 70710-1472

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 70710-1472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 01)

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 02)

This document provides guidance on changing dosage due to PK measures, including fold change and recommendations, with 90% confidence intervals. It discusses the impact of strong CYP3A4 inhibitors such as Keloconazole, Verapamil, and others on the use of various medications like Diltiazem, Grapefruit juice, and others. It also suggests dose adjustments for medications such as Sildenafil, Lacidipine, Simvastatin, Lansoprazole, Omeprazole, and Warfarin relative to Nabradine alone.*

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 03)

This text provides data on the proportion of patients with heart failure hospitalization or cardiovascular death over time for a placebo group and a group treated with Ivabradine. The graph shows a comparison between the two groups over a 36-month period. The number of subjects at risk is also displayed for each time point.*

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 04)

FDA Label Image

5 mg (Cbea8583 E207 402a B79a 83ff14a3fa9b 05)

FDA Label Image

7.5 mg (Cbea8583 E207 402a B79a 83ff14a3fa9b 06)

Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.